OXFORD COVID-19 VACCINE : AZD1222
OXFORD COVID-19 VACCINE : AZD1222
The vaccine did not prompt any serious side effects and elicited antibody and T-cell immune responses, according to trial results published in The Lancet medical journal.
London:
An experimental COVID-19 vaccine, being developed by the University of Oxford, was safe and produced an immune response in early-stage clinical trials in healthy volunteers, data showed on Monday.
The vaccine, called AZD1222 and being developed by pharmaceutical company AstraZeneca and scientists at Britain's University of Oxford, did not prompt any serious side effects and elicited antibody and T-cell immune responses, according to trial results published in The Lancet medical journal.
Comments
Post a Comment